Headlines about Shire PLC (NASDAQ:SHPG) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Shire PLC earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 83 out of 100, meaning that recent press coverage is very likely to have an effect on the stock’s share price in the near future.
These are some of the media stories that may have effected Accern’s scoring:
- At the Focal Point, Checking in on Shire plc (NASDAQ:SHPG) and Illinois Tool Works Inc. (NYSE:ITW) – FLBC News (flbcnews.com)
- Shire PLC (SHPG) Given Consensus Rating of “Buy” by Analysts (americanbankingnews.com)
- Bienville Capital Management LLC Has $429000 Stake in Shire PLC (SHPG) (ekosvoice.com)
- Biocryst and Shire under pressure on FDA approval of Behring’s HAE med (seekingalpha.com)
- Shire PLC (SHPG) Upgraded at BidaskClub (americanbankingnews.com)
A number of brokerages have recently issued reports on SHPG. BidaskClub raised Shire PLC from a “strong sell” rating to a “sell” rating in a research report on Friday, June 23rd. Cantor Fitzgerald started coverage on Shire PLC in a research report on Friday, June 16th. They set an “overweight” rating and a $222.00 price target on the stock. Stifel Nicolaus dropped their price target on Shire PLC from $250.00 to $245.00 and set a “buy” rating on the stock in a research report on Friday, June 9th. Jefferies Group LLC reissued a “buy” rating and set a $216.00 price target (down from $239.00) on shares of Shire PLC in a research report on Friday, June 9th. Finally, Royal Bank Of Canada set a $218.00 price target on Shire PLC and gave the company a “buy” rating in a research report on Thursday, June 8th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and sixteen have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $223.01.
Shares of Shire PLC (NASDAQ SHPG) traded up 0.19% on Wednesday, reaching $172.23. The company’s stock had a trading volume of 746,582 shares. The company has a 50 day moving average price of $176.62 and a 200 day moving average price of $174.09. The company has a market cap of $51.30 billion, a P/E ratio of 176.65 and a beta of 1.57. Shire PLC has a 52-week low of $161.09 and a 52-week high of $209.22.
Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $3.63 EPS for the quarter, topping analysts’ consensus estimates of $3.22 by $0.41. Shire PLC had a return on equity of 13.05% and a net margin of 2.14%. The business had revenue of $3.57 billion during the quarter. During the same quarter in the previous year, the business posted $2.12 EPS. The company’s revenue for the quarter was up 109.0% on a year-over-year basis. On average, analysts anticipate that Shire PLC will post $14.90 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://sportsperspectives.com/2017/06/28/somewhat-favorable-news-coverage-very-likely-to-impact-shire-plc-shpg-share-price.html.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.